# Jiangsu Recibio Technology CO.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-recibio-technology-co

- Industry: Biotechnology
- Headquarters: Taizhou, China
- Website: www.recbio.cn
- Total disclosed funding: $383M
- Latest round: Series C (Jun 12, 2021)
- Investors on record: 25

## About

Founded in 2012 and based in Taizhou, China, Jiangsu Recibio Technology CO., Ltd. previous known as RecBio, operates as a biotechnology company that specializes in the development of genetic engineering vaccines. In January 2019, the company merged with Anbaisheng Biotechnology. In March 2022, the company was listed on the Hongkong Stock Exchange under the number 02179. 

The company has a vaccines candidates portfolio consisting of 12 vaccine candidates, including recombinant HPV vaccine, recombinant COVID-19 vaccine, recombinant shingles vaccine, Virus vector adult TB vaccine, recombinant influenza quadrivalent vaccine. The company's core product is the recombinant HPV 9-valent vaccine to prevent cervical cancer which is currently under phase III clinical trial. For the recombinant HPV 9-valent vaccine, REC603, the company has completed subject enrollment and plans to complete the three-shot dosing in the first half of 2022, and to submit the BLA application to the NMPA by 2025. Also, the company developed two recombinant HPV bivalent vaccine candidates, REC601 and REC602, which both are under phase I clinical trial in China.

The company plans to continue to optimize, develop and commercialize the HPV vaccine pipeline, perform preclinical and clinical studies, registration of COVID-19 vaccine, and other vaccines.

## Funding rounds

- Series C, Jun 12, 2021, $156M — Temasek Holdings, Sage Partners, Boyu Capital, E Fund Management Co.,Ltd, BC Capital, Lake Bleu Capital, Valliance Capital
- Series B, Nov 11, 2020, $227M — Hong Shan, Legend Capital, China Everbright, Oriental Fortune Capital, CoStone Capital, Qingsong Fund, YuanBio Venture, LYFE Capital, Vertex Ventures China, Tsing Song Capital, Haitong Kaiyuan, HT Capital, FER Capital, Beijing Zhiming Haojin Investment Management
- Series A, Jan 25, 2019 — Oriental Fortune Capital, CR Capital, CMB International Asset Management, Taizhou China Medicine Chengrong Jianda Venture Investment
- Angel, Feb 28, 2017 — Hongxun Capital Cci Capital

## Investors

- Hongxun Capital Cci Capital (https://capitalatlas.ai/funds/hongxun-capital-cci-capital) — Angel
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A, Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series A
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Taizhou China Medicine Chengrong Jianda Venture Investment — Series A
- Hong Shan — Series B
- Legend Capital — Series B
- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series B
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series B
- Qingsong Fund (https://capitalatlas.ai/funds/qingsong-fund) — Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- LYFE Capital — Series B
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series B
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series B
- Haitong Kaiyuan — Series B
- HT Capital — Series B
- FER Capital (https://capitalatlas.ai/funds/fer-capital) — Series B
- Beijing Zhiming Haojin Investment Management — Series B
- Temasek Holdings — Series C
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series C
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series C
- E Fund Management Co.,Ltd — Series C
- BC Capital — Series C
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C
- Valliance Capital — Series C